RUMORED BUZZ ON ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

In Section A, individuals will receive different doses and schedules of oral ABBV-744 pill to recognize Protected dosing regimen. Further participants will be enrolled within the determined monotherapy dosign regimen. In Section B, individuals will acquire oral ruxolitinib and ABBV-744 is going to be provided as "add-on" therapy. In Section C, part